ClinicalTrials.gg
RecruitingNCT07502677Updated Mar 31, 2026

Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Sclerosis

An observational study in Amyotrophic Lateral Sclerosis, sponsored by Royal Brompton & Harefield NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Royal Brompton & Harefield NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom — 15 open to participants now, 22 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · United Kingdom.

Planned enrollment
13th of 15
15 · median 73
Started
2026
with 6 others
Observational
15 of 70
8 open now
Primary completion
2026-09
later than 9 of 21 live
Registered
66th of 70
by date

Among the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 15 observational ones that give a count, is one of 7 that started in 2026, is one of 15 observational ones, reaches primary completion later than 9 of the 21 other live ones, and was the 66th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, or all of them as a file.
02

Study summary

The specific aim of this study is to try to discover the diagnostic accuracy of SleepImage technology for detecting respiratory failure in patients with MND. Importantly, this research project is not about NIV, it is about what method can most efficiently decide when to start NIV.

To do this we'd like to collect data about you and your breathing from the SleepImage device when you come in for your routine overnight sleep study. We will compare this against the data that we would collect anyway.

Read the detailed description

In general, where lung mechanics are normal, oxygen (O2) levels are the reciprocal of carbon dioxide (CO2) levels. However, due to the sigmoid shape of the oxygen dissociation curve peripheral capillary measurement of O2 (SpO2) via pulse oximeter does not provide adequate warning of respiratory failure in ALS. Advancements in sleep diagnostic equipment has allowed for the SleepImage System in addition to measuring SpO2, to also use tonometry to assesses autonomic output during sleep. SleepImage is US Food and Drug Administration, FDA-cleared and European Union Medical Device Regulatory EU-MDR compliant (CE-marked medical device). Specifically, SleepImage determines sleep architecture based on the strength of synchronisation between signals from the cardiovascular system (pulse rate variability) and respiratory system (tidal volume variability), based on cardiopulmonary coupling (CPC) analysis. Three distinct patterns of CPC are detected; (1) stable sleep (high-frequency coupling, HFC;0.1-0.4Hz) including all electroencephalogram estimated NREM-3 and part of NREM-2 sleep, associated with periods of stable breathing, non-cyclic alternating pattern (CAP) on the EEG, increased delta power and blood pressure dipping, (2) unstable sleep (low-frequency coupling, LFC;0.01-0.1Hz) including all NREM-1 and portion of NREM-2 associated with sleep instability, characterized by variability in tidal volumes, blood pressure non-dipping and CAP on EEG, (3) Wake and rapid eye movement (REM) sleep (very low-frequency coupling characteristics, vLFC;0-0.01Hz). The device can identify potential sleep pathologies evidenced by activity in a subset of unstable sleep where two discernible bands emerge; (1) a broad-spectral-band e-LFC (eLFCBB), linked to sleep fragmentation and obstructive sleep apnoea and (2) a narrow-spectral-band e-LCC (eLFCNB) in the frequency range 0.0006 to 0.1Hz, indicative of putative central sleep apnoea, periodic breathing or complex sleep apnoea. These metrics are expressed as a percentage of analysis windows related to the total sleep period. Other SleepImage diagnostic parameters include the Sleep Quality Index (SQI) which is biomarker and objective score of overall sleep quality. SQI integrates sleep stability, fragmentation, sleep duration and sleep pathologies derived from CPC and is presented on a scale of 0-100, apnoea hypopnea index , hypoxic burden , sleep onset, sleep offset, sleep duration, total sleep time , wake after sleep onset and sleep efficiency. At a practical level, the SleepImage device is a single patient, multiple use device which can be posted to the patient's home. It thus permits a sleep study assessment on as frequent as a basis as the physician and patient wish within the home setting.

The aim of this feasibility study is to review the efficacy of the SleepImage diagnostic equipment as a predictor of ventilatory impairment. This will be determined by a sleep quality index SQI of \<55 and Periodicity (eLFCNB) >2 showing an association with ventilatory failure.

The use of the SleepImage technology would not be to replace current diagnostic tests such as SNIP, VC, TcCO2 and blood gases, but instead used as an early screen tool. If a positive association can be made between SQI, Periodicity and ventilatory failure, then SleepImage technology could be used as a tool to expedite the process of hospital diagnostic tests to assess for ventilatory impairment. Furthermore, the SleepImage technology could be used once patients are established onto ventilation as a way of monitoring their ventilatory control on therapy.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Amyotrophic Lateral Sclerosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 and over with a Neurologist confirmed diagnosis of ALS

Exclusion criteria

Exclusion Criteria:

  • Patients with known respiratory disease
  • Unstable cardiac disease, stable hypertension or ischaemic heart disease
  • Current NIV use
  • Inability to give consent (expected \~15% due to frontotemporal dementia)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Groups and cohorts

  • Diagnosis of ALS without NIV

    Device: SleepImage

Interventions

  • DeviceSleepImage

    SleepImage Device

06

What researchers measure

Primary outcomes

  1. SQI & e-LFCNB>2

    We hypothesise that a SQI \<55 and Periodicity e-LFCNB\>2 has a positive association with an accepted indication for NIV initiation in ALS defined as: * Daytime Carbon Dioxide \>6.0kPa and a rise of \>1kPa from baseline in a time course consistent with REM sleep * Bicarbonate levels \>32mmol/L * SNIP \<40cmH20 in patients with non-bulbar disease * Supine fall in VC of 20% from erect in patient able to undertake the manoeuvre

    Time frame: 12 hours

Secondary outcomes

  1. Hypoxic burden, T90, Pulse rate variability

    The secondary endpoints of the study are to evaluate additional outputs generated by the SleepImage device and determine their association with the same established clinical criteria for NIV initiation in ALS. Specifically, the secondary analyses will focus on: * Hypoxic burden * SpO₂ time below 90% (T90). * Pulse rate variability

    Time frame: 12 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.

Of 129 non-industry observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 125. This study's planned 5 months is below that.

Counting every sponsor, half of 138 studies reached it within 64 months; a quarter within 29 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 31, 2026
StartActual
Mar 24, 2026
Primary completionEst.
Sep 1, 2026
CompletionEst.
Mar 24, 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07502677
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Mar 24, 2026
Primary completion
Sep 1, 2026 (estimated)
Completion
Mar 24, 2027 (estimated)
Last update
Mar 31, 2026

Study contacts

Professor Michael Polkey
Contact
mike.polkey@nhs.net
020 7352 8121
Lucy Redmond
Contact
lucy.redmond4@nhs.net

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion